Details

Autor(en) / Beteiligte

• Li, Lili
• Gao, Meiling
• Jiao, Peng
• Zu, Shulong
• Deng, Yong-Qiang
• Wan, Dingyi
• Cao, Yang
• Duan, Jing
• Aliyari, Saba R
• Li, Jie
• Shi, Yueyue
• Rao, Zihe
• Qin, Cheng-Feng
• Guo, Yu
• Cheng, Genhong
• Yang, Heng

Titel

Antibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants

Ist Teil von

• Cell & bioscience, 2022-05, Vol.12 (1), p.63-63, Article 63

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2022

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Neutralizing antibodies are approved drugs to treat coronavirus disease-2019 (COVID-19) patients, yet mutations in severe acute respiratory syndrome coronavirus (SARS-CoV-2) variants may reduce the antibody neutralizing activity. New monoclonal antibodies (mAbs) and antibody remolding strategies are recalled in the battle with COVID-19 epidemic. We identified multiple mAbs from antibody phage display library made from COVID-19 patients and further characterized the R3P1-E4 clone, which effectively suppressed SARS-CoV-2 infection and rescued the lethal phenotype in mice infected with SARS-CoV-2. Crystal structural analysis not only explained why R3P1-E4 had selectively reduced binding and neutralizing activity to SARS-CoV-2 variants carrying K417 mutations, but also allowed us to engineer mutant antibodies with improved neutralizing activity against these variants. Thus, we screened out R3P1-E4 mAb which inhibits SARS-CoV-2 and related mutations in vitro and in vivo. Antibody engineering improved neutralizing activity of R3P1-E4 against K417 mutations. Our studies have outlined a strategy to identify and engineer neutralizing antibodies against SARS-CoV-2 variants.